C4 Therapeutics (CCCC) Stock Price, News & Analysis

Company Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages. Lead programs are directed at hematologic malignancies, solid tumors and other serious diseases. C4 Therapeutics has established strategic collaborations with major pharmaceutical partners to leverage its CiD platform across various therapeutic areas. These partnerships provide access to joint research and development resources, accelerating the advancement of novel degrader molecules into human studies.

Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics operates research laboratories in the United States and collaborates with academic institutions and contract research organizations worldwide. The company employs a multidisciplinary team of chemists, biologists and drug development experts to drive its discovery engine and translate early-stage assets into clinical candidates.

C4 Therapeutics is led by a management team with extensive experience in protein chemistry, drug discovery and clinical development. The company’s leadership includes seasoned biotechnology executives and scientific advisors who guide its efforts to bring next-generation protein degraders to patients. Through its innovative platform, C4 Therapeutics aims to expand the therapeutic possibilities for diseases driven by previously “undruggable” targets.

Key Stats

• Today's Range: $2.89 to $3.07
• 50-Day Range: $2.30 to $3.59
• 52-Week Range: $1.21 to $3.82
• Volume: 1.19 million shs
• Average Volume: 3.40 million shs
• Market Capitalization: $327.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Moderate Buy

C4 Therapeutics Stock Analysis - MarketRank™

C4 Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 584th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

C4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

C4 Therapeutics has a consensus price target of $7.75, representing about 160.9% upside from its current price of $2.97.

Amount of Analyst Coverage

C4 Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.01) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of C4 Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of C4 Therapeutics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

C4 Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.63% of the float of C4 Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

C4 Therapeutics has a short interest ratio ("days to cover") of 5.05.

Change versus previous month

Short interest in C4 Therapeutics has recently increased by 30.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

C4 Therapeutics does not currently pay a dividend.

Dividend Growth

C4 Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.97

News Sentiment

C4 Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.

Search Interest

28 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 833% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.73% of the stock of C4 Therapeutics is held by insiders.

Percentage Held by Institutions

78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CCCC Stock Analysis - Frequently Asked Questions

How have CCCC shares performed this year?

C4 Therapeutics' stock was trading at $1.91 at the start of the year. Since then, CCCC shares have increased by 55.5% and is now trading at $2.97.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) released its quarterly earnings results on Thursday, February, 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.25. The company earned $11.02 million during the quarter, compared to the consensus estimate of $4.48 million. C4 Therapeutics had a negative net margin of 292.08% and a negative trailing twelve-month return on equity of 53.83%.

When did C4 Therapeutics IPO?

C4 Therapeutics (CCCC) raised $163 million in an initial public offering on Friday, October 2nd 2020. The company issued 9,600,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' top institutional shareholders include Wasatch Advisors LP (3.04%). Insiders that own company stock include Leonard Reyno and Scott N Boyle.
View institutional ownership trends.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of C4 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CCCC
• CIK: 1662579
• Web: www.c4therapeutics.com
• Phone: 617-231-0700
• Fax: N/A
• Employees: 150
• Year Founded: 2015

Price Target and Rating

• Average Price Target for C4 Therapeutics: $7.75
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +160.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$104.99 million
• Net Margins: -292.08%
• Pretax Margin: -291.74%
• Return on Equity: -53.83%
• Return on Assets: -33.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.81
• Quick Ratio: 7.81

Sales & Book Value

• Annual Sales: $35.95 million
• Price / Sales: 9.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 110,180,000
• Free Float: 89,059,000
• Market Cap: $327.23 million
• Optionable: Optionable
• Beta: 2.77